May 21, 2009

A Phase II Trial of Denileukin Diftitox in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

Denileukin diftitox at current dose schedule has limited activity in patients with previously treated NSCLC, manifested by disease control without impact on survival.

Mark Helpful

Bookmark

Relay

Mark Helpful

Bookmark

Relay

Cite This Study

Gerena-Lewis et al. (Thu,) studied this question.

synapsesocial.com/papers/69d990b9387cf706986848a1 https://doi.org/https://doi.org/10.1097/coc.0b013e318187dd40

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The clinical significance of serum soluble interleukin 2 receptor (sIL-2R) concentration in lung cancer.2001 · 13 citations
2Soluble interleukin-2 receptors and other markers in primary lung cancer1991 · 30 citations
3The IL-2 Receptor Complex: Its Structure, Function, and Target Genes1993 · 608 citations
4Internalization of interleukin 2 is mediated by the beta chain of the high-affinity interleukin 2 receptor.1987 · 232 citations
5Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.1995 · 259 citations